The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2023 | Insights into mass spectrometry-based proteomics in multiple myeloma research
Arun Wiita, PhD, University of California, San Francisco, CA, shares some insights into the use of mass spectrometry-based proteomics in multiple myeloma, highlighting the value of this novel approach in improving research in the field. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research funding: Roche/Genentech
